Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.
Alessio Carbone, Elena Biagioli, Vanda Salutari...
https://pubmed.ncbi.nlm.nih.gov/41392465/Actively Recruiting
Led by Ente Ospedaliero Ospedali Galliera · Updated on 2025-01-27
132
Participants Needed
19
Research Sites
N/A
Total Duration
Researchers are evaluating whether letrozole is more effective than standard chemotherapy for treating patients with hormone receptor positive low-grade serous epithelial ovarian carcinoma LGSCO. This phase III, open-label, randomized trial aims to see if letrozole can extend progression-free survival compared to carboplatin and paclitaxel chemotherapy. The study also explores tumor response, quality of life, pain, overall survival, safety, and genetic markers related to the disease. Participants will be randomly assigned to one of two groups one group takes letrozole tablets daily by mouth for up to 60 months or until disease progression, while the other group receives carboplatin and paclitaxel intravenously on day 1 every 21 days for 6 to 8 cycles. The treatments are compared directly to assess their effects on cancer control and patient well-being. During the study, participants will have regular assessments including tumor response evaluations, quality of life questionnaires, pain inventory, and safety monitoring according to standard criteria. Genetic profiling and circulating tumor DNA will be analyzed to understand disease characteristics. Progression-free survival will be tracked for up to 84 months, with ongoing monitoring of overall survival and adverse events. Participants will be followed closely to observe treatment effects and side effects throughout the trial period.
CONDITIONS
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
A
Andrea DeCensi, Prof.
M
Marianna Fava, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ente Ospedaliero Ospedali Galliera
Lead Sponsor
Istituto Di Ricerche Farmacologiche Mario Negri
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 months for letrozole or approximately 18 to 24 weeks for chemotherapy
Participants receive either letrozole tablets daily until disease progression or up to 60 months, or receive carboplatin and paclitaxel chemotherapy intravenously every 21 days for 6 to 8 cycles.
Day 1 visits every 21 days for 6 to 8 cycles for chemotherapy; daily oral administration for letrozole
Duration - Up to 84 months
Participants are monitored for progression-free survival, overall survival, response rates, and safety after treatment ends.
Periodic visits as scheduled for monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alessio Carbone, Elena Biagioli, Vanda Salutari...
https://pubmed.ncbi.nlm.nih.gov/41392465/Ente Ospedaliero Ospedali Galliera
Lead Sponsor
Istituto Di Ricerche Farmacologiche Mario Negri
Collaborating Sponsor